AnaptysBio, Inc. (NASDAQ:ANAB)‘s stock had its “buy” rating reissued by investment analysts at Stifel Nicolaus in a report released on Tuesday. They presently have a $35.00 price target on the biotechnology company’s stock. Stifel Nicolaus’ price objective would indicate a potential upside of 8.02% from the stock’s current price.

Other research analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of AnaptysBio from a “buy” rating to a “hold” rating in a report on Tuesday, August 29th. Robert W. Baird began coverage on shares of AnaptysBio in a report on Monday, July 10th. They set an “outperform” rating and a $36.00 price target for the company. Finally, Credit Suisse Group boosted their price target on shares of AnaptysBio from $34.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, August 25th. Six investment analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $36.00.

AnaptysBio (NASDAQ:ANAB) traded up 0.880% during midday trading on Tuesday, reaching $32.685. 116,512 shares of the company were exchanged. AnaptysBio has a 52 week low of $15.17 and a 52 week high of $33.58. The company’s market capitalization is $664.88 million. The firm has a 50-day moving average price of $24.56 and a 200-day moving average price of $25.08.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.29. The firm had revenue of $7.00 million for the quarter, compared to analyst estimates of $3.45 million. Equities research analysts anticipate that AnaptysBio will post ($1.96) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/12/stifel-nicolaus-reiterates-buy-rating-for-anaptysbio-inc-anab.html.

In other news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total transaction of $901,924.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Holdings A/S Novo sold 70,706 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $23.31, for a total transaction of $1,648,156.86. Following the sale, the insider now owns 3,009,949 shares of the company’s stock, valued at approximately $70,161,911.19. The disclosure for this sale can be found here. Insiders have sold a total of 1,133,940 shares of company stock valued at $24,223,316 in the last 90 days.

Several large investors have recently modified their holdings of the company. DAFNA Capital Management LLC lifted its position in shares of AnaptysBio by 22.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock worth $132,000 after buying an additional 1,000 shares during the last quarter. Teachers Advisors LLC raised its position in AnaptysBio by 23.4% in the 2nd quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 1,807 shares during the last quarter. Bank of America Corp DE purchased a new stake in AnaptysBio in the 1st quarter valued at $123,000. TIAA CREF Investment Management LLC raised its position in AnaptysBio by 69.2% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 13,844 shares of the biotechnology company’s stock valued at $331,000 after purchasing an additional 5,663 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in AnaptysBio by 46.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 19,744 shares of the biotechnology company’s stock valued at $473,000 after purchasing an additional 6,297 shares during the last quarter. Institutional investors and hedge funds own 71.35% of the company’s stock.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Stock Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related stocks with our FREE daily email newsletter.